## **Stem Cell Therapy Brings New Hope For Spinal Cord And Brain Injury Patients**

**Kuang Tien General Hospital Showcases Clinical Success Stories** 



**New York City, New York May 5, 2025 (<u>Issuewire.com</u>) - Kuang Tien General Hospital today hosted the "Spinal Cord Injury Cell Therapy Presentation" at its Xiangshang Campus in Shalu District, Taichung, unveiling notable clinical results in the application of stem cell therapy for spinal cord and brain injury patients.** 

The event was attended by Chief Superintendent Dr. Nai-Hong Wang, Superintendent Dr. Zi-yong Chen, Deputy Superintendent Dr. Jia Zhu Chang of Kuang Tien General Hospital, and Chairman Mr. Wen-Long Su of Taiwan Advance Bio-Pharmaceutical Inc. (TABP).

At the presentation, Dr. Zi-yong Chen showcased significant improvements observed among patients treated with stem cell therapy, including enhanced sensation, muscle tone, sphincter control, self-care capabilities, and emotional expression. Notably, a 34-year-old male patient who had suffered from intracranial hemorrhage combined with spinal fracture, and was left paralyzed from the waist down, regained the ability to sit up independently after treatment and has shown progressive recovery of leg sensation and strength. Another case involved a 12-year-old boy with impaired motor coordination due to early brain damage. Following therapy, he demonstrated stable walking, successfully completed balance tests, and exhibited marked improvements in cognitive and verbal communication abilities.

Dr. Nai-Hong Wang emphasized the hospital's commitment to a "patient-centered" philosophy and its dedication to clinical innovation. Through regenerative medicine, the hospital enables patients to overcome the limitations of conventional therapies. The event also marked the inauguration of the Xiangshang Campus as a hub for advanced medical services.

Dr. Chen elaborated that stem cell infusion methods are tailored to each patient's condition, using techniques such as in-situ injection and intrathecal injection (i.e., injection into the spinal canal). Over the past year, many patients have shown neurological recovery and functional improvement. Notably, patients with brain injuries have shown clear signs of central nervous system regeneration.

Since 2022, Kuang Tien has accumulated over 40 clinical cases, demonstrating its strengths in surgical techniques, interdisciplinary teamwork, and family engagement. One of the hospital's oldest patients, a 75-year-old, progressed from struggling to grasp objects to independently using chopsticks—an inspiring testament to the therapy's power.

"This is just the beginning," said Dr. Chen. "We are eager to share our results with the broader community and to continue pushing the boundaries of regenerative treatment."

This initiative is a collaboration between Kuang Tien and Taiwan Advanced Bio-Pharmaceutical Inc. (TABP), which provides autologous bone marrow mesenchymal stem cells and their derived exosomes under Taiwan's official "Regulations Governing the Application of Specific Medical Techniques or Examinations." Chairman Mr. Wen-Long Su of TABP emphasized the importance of this partnership in promoting clinical adoption and expanding patient access.

## **Images and Captions**

Figure 1: Kuang Tien General Hospital with TABP hosted the "Spinal Cord Injury Cell Therapy Presentation".

Figure 2: Dr. Nai-Hong Wang emphasized the hospital has helped patients transcend the limitations of conventional therapies.

Figure 3: Chairman Mr. Wen-Long Su expressed that TABP has partnered with the Kuang Tien medical system to further promote the development of cell therapy for spinal cord injuries.

Figure 4: Dr. Ziyong Chen said the hospital is dedicated to advancing the field and sharing its outcomes with broader communities.

Figure 5: Baseball player Qin Qien, who was paralyzed by a car accident, poses with his mother. He is actively involved in rehabilitation and treatment.

Figure 6: TABP has a professional laboratory that is able to grow high-quality cells.



## **Media Contact**

Prestige Cybermedia Co., LTD.

\*\*\*\*\*\*\*@gmail.com

Source: Prestige Cybermedia Co., LTD.

See on IssueWire